Treatment of Splenic Marginal Zone Lymphoma: Splenectomy Versus Rituximab
- 1 April 2010
- journal article
- research article
- Published by Elsevier in Seminars in Hematology
- Vol. 47 (2) , 143-147
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Rituximab monotherapy is highly effective in splenic marginal zone lymphomaHematological Oncology, 2008
- Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteriaLeukemia, 2007
- Rituximab monotherapy is highly effective in splenic marginal zone lymphomaHematological Oncology, 2007
- Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy aloneCancer, 2006
- Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patientsBritish Journal of Haematology, 2003
- Treatment of Splenic Marginal Zone B-Cell Lymphoma: An Analysis of 81 PatientsClinical Lymphoma, 2002
- Splenic lymphoma with villous lymphocytes: clinical presentation, biology and prognostic factors in a series of 100 patientsBritish Journal of Haematology, 1996
- The immunophenotype of splenic lymphoma with villous lymphocytes and its relevance to the differential diagnosis with other B-cell disordersBlood, 1994
- Splenic Marginal Zone Cell LymphomaAmerican Journal of Surgical Pathology, 1992
- Splenic lymphoma with villous lymphocytes: natural history and response to therapy in 50 casesBritish Journal of Haematology, 1991